JP2007509116A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509116A5
JP2007509116A5 JP2006536167A JP2006536167A JP2007509116A5 JP 2007509116 A5 JP2007509116 A5 JP 2007509116A5 JP 2006536167 A JP2006536167 A JP 2006536167A JP 2006536167 A JP2006536167 A JP 2006536167A JP 2007509116 A5 JP2007509116 A5 JP 2007509116A5
Authority
JP
Japan
Prior art keywords
methyl
nitro
phenylamino
trifluoromethyl
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509116A (ja
Filing date
Publication date
Priority claimed from GBGB0324551.1A external-priority patent/GB0324551D0/en
Application filed filed Critical
Publication of JP2007509116A publication Critical patent/JP2007509116A/ja
Publication of JP2007509116A5 publication Critical patent/JP2007509116A5/ja
Pending legal-status Critical Current

Links

JP2006536167A 2003-10-21 2004-10-21 アンドロゲン受容体モジュレーター Pending JP2007509116A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324551.1A GB0324551D0 (en) 2003-10-21 2003-10-21 Novel compounds
PCT/GB2004/004464 WO2005042464A1 (en) 2003-10-21 2004-10-21 Androgen receptor modulators

Publications (2)

Publication Number Publication Date
JP2007509116A JP2007509116A (ja) 2007-04-12
JP2007509116A5 true JP2007509116A5 (enExample) 2007-12-06

Family

ID=29595536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536167A Pending JP2007509116A (ja) 2003-10-21 2004-10-21 アンドロゲン受容体モジュレーター

Country Status (7)

Country Link
US (1) US20080058383A1 (enExample)
EP (1) EP1685090A1 (enExample)
JP (1) JP2007509116A (enExample)
AU (1) AU2004285744A1 (enExample)
CA (1) CA2543345A1 (enExample)
GB (1) GB0324551D0 (enExample)
WO (1) WO2005042464A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009902B1 (ru) 2004-02-13 2008-04-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Модуляторы рецепторов андрогенов
JP2007532621A (ja) 2004-04-13 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレータ
BRPI0509980A (pt) 2004-04-22 2007-10-16 Warner Lambert Co moduladores de androgênio
MXPA06013115A (es) * 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
MXPA06015169A (es) 2004-07-08 2007-08-21 Warner Lambert Co Moduladores de androgenos.
JP2008515998A (ja) * 2004-10-13 2008-05-15 スミスクライン ビーチャム コーポレーション 化合物
NZ555974A (en) 2005-01-10 2010-11-26 Acadia Pharm Inc Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP2051935B1 (en) * 2006-07-26 2016-09-07 STMicroelectronics Srl Use of nitroaniline derivatives for the production of nitric oxide
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
KR101719550B1 (ko) 2008-07-02 2017-03-24 브리티쉬 콜롬비아 캔써 에이전시 브랜치 디글리시드 에테르 유도체 치료법 및 이의 사용 방법
BRPI0921185A2 (pt) 2008-11-24 2018-05-29 Basf Se composição curável, artigo para revestimento ou ligado, uso de um composto, e, composto
KR20100067046A (ko) * 2008-12-10 2010-06-18 동화약품주식회사 신규한 ２，６―위치에 치환된 ３―니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
CA2748813C (en) 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
FR2954315B1 (fr) 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954316B1 (fr) 2009-12-23 2014-01-03 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2011082487A1 (en) 2010-01-06 2011-07-14 British Columbia Cancer Agency Branch Bisphenol derivatives and their use as androgen receptor activity modulators
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US20130109019A1 (en) * 2010-07-02 2013-05-02 Adrian E. Murillo Hapten conjugates for target detection
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas PRO-NEUROGENIC COMPOUNDS
WO2015031984A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US9586933B2 (en) 2014-12-23 2017-03-07 Gilead Sciences, Inc. Processes for preparing ASK1 inhibitors
FI3988541T3 (fi) 2015-01-13 2024-09-17 British Columbia Cancer Agency Branch Heterosyklisiä yhdisteitä syövän kuvantamiseksi ja hoitamiseksi ja menetelmiä niiden käyttämiseksi
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
EP3625215B1 (en) 2017-05-18 2023-09-13 PI Industries Ltd Formimidamidine compounds useful against phytopathogenic microorganisms
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EP4135675A4 (en) * 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970423A (en) * 1971-10-04 1976-07-20 Clairol Incorporated Oxidative hair dye compositions
CA1012553A (en) 1972-06-23 1977-06-21 Hirotoshi Nakanishi Process for the production of aromatic diamines
JPS4920129A (enExample) * 1972-06-23 1974-02-22
US4723986A (en) 1986-05-19 1988-02-09 Stauffer Chemical Company Herbicidal oxazolidines and methods of use
JP2701090B2 (ja) * 1990-11-30 1998-01-21 和光純薬工業株式会社 被酸化性呈色試薬
JPH0580375A (ja) * 1991-09-20 1993-04-02 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
JPH0920129A (ja) * 1995-07-05 1997-01-21 Suzuki Motor Corp 車両用暖房装置
DE19612506A1 (de) 1996-03-29 1997-10-02 Wella Ag Oxidationshaarfärbemittel mit einem Gehalt an 2,5-Diaminobenzonitrilen sowie neue 2,5-Diaminobenzonitrile
US6569896B2 (en) * 2000-08-24 2003-05-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
EP1042295B1 (en) * 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
US20020193389A1 (en) * 1998-11-20 2002-12-19 Rifat Pamukeu Method of inhibiting neoplastic cells with imidazoquinazoline derivatives
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2002020495A2 (en) * 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
DE10163251A1 (de) * 2001-12-21 2003-07-03 Henkel Kgaa Neue Entwicklerkomponenten

Similar Documents

Publication Publication Date Title
EP2516398B1 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US5776951A (en) Anti-atherosclerotic diaryl compounds
JP2015526487A5 (enExample)
CZ20032727A3 (cs) Derivát karboxylové kyseliny a jeho sůl
FR2954315A1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
EP1731506A1 (en) 5-hydroxyindole-3-carboxylates derivatives and their use
JP7443414B2 (ja) アンドロゲン受容体のｎ末端ドメインの阻害剤
JP2007509116A (ja) アンドロゲン受容体モジュレーター
CS242881B2 (en) Method of 1,4-dihydropyridine's new derivatives production
SK13752002A3 (sk) Difenyléterové zlúčeniny užitočné pri liečení
CZ334998A3 (cs) Substituované benzylaminy a farmaceutický prostředek
CN1192728A (zh) 苯基烷烃酰胺衍生物及农业或园艺杀菌剂
SK285037B6 (sk) Spôsob výroby 2-aryl-3-aryl-5-halogénpyridínov
TWI284127B (en) Cyclization process for substituted benzothiazole derivatives
CN1197864C (zh) 吡唑并哒嗪衍生物的制备方法
CN1317265C (zh) 氰基丙烯酸酯衍生物及制备方法和生物活性
CN1533378A (zh) 制备喹唑啉的方法
CN107848968B (zh) 从乙醛酸制备内酰胺的方法
EP2516400B1 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
TWI884201B (zh) 用於製備3-溴-1-(3-氯吡啶-2-基)-1h-吡唑-5-羧酸乙酯的方法
AU2010303243A1 (en) Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
CN1166650C (zh) 1,2,3-噻二唑类化合物及其制备方法和生物活性
EP1928869B1 (en) Chemical process
CN100363347C (zh) 作为治疗剂的4-(1-(磺酰基)-1h-吲哚-2-基)-4-(羟基)-环己-2,5-二烯酮化合物及其类似物
CN1939127A (zh) 取代苯基异噁唑类除草剂